SCHEMBL659587

SCHEMBL659587

NC1(C(=O)O)C[C@H](C(=O)O)[C@H](C(=O)O)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 7/20 1.00
CYP1A2 P05177 4/20 1.00
CYP2C19 P33261 3/20 1.00
ALDH1A1 P00352 2/20 1.00
TDP1 Q9NUW8 2/20 1.00
GRM8 O00222 2/20 1.00
GRM6 O15303 2/20 1.00
MEN1 O00255 1/20 1.00
KMT2A Q03164 1/20 1.00
CYP2D6 P10635 1/20 1.00
CYP2C9 P11712 1/20 1.00
ALOX15 P16050 3/20 0.65
KDM4E B2RXH2 1/20 0.65
GRM2 Q14416 4/20 0.50
GRM3 Q14832 4/20 0.50
LMNA P02545 1/20 0.50
GRM5 P41594 1/20 0.50
MTOR P42345 1/20 0.50
GRM1 Q13255 1/20 0.50
PLCB1 Q9NQ66 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3954836 1.00 GRM4 (1.00) GRM4CYP1A2CYP2C19ALDH1A1TDP1
SCHEMBL8476727 1.00 GRM4 (1.00) GRM4CYP1A2CYP2C19ALDH1A1TDP1
SCHEMBL659588 1.00 GRM4 (1.00) GRM4CYP1A2CYP2C19ALDH1A1TDP1
SCHEMBL12648585 1.00 GRM4 (1.00) GRM4CYP1A2CYP2C19ALDH1A1TDP1
SCHEMBL13319984 1.00 GRM4 (1.00) GRM4CYP1A2CYP2C19ALDH1A1TDP1
SCHEMBL3328641 1.00 GRM4 (1.00) GRM4CYP1A2CYP2C19ALDH1A1TDP1
SCHEMBL1064244 0.79 CYP1A2 (1.00) GRM4CYP1A2CYP2C19ALDH1A1TDP1
SCHEMBL1063416 0.79 CYP1A2 (1.00) GRM4CYP1A2CYP2C19ALDH1A1TDP1
SCHEMBL1263461 0.79 CYP1A2 (1.00) GRM4CYP1A2CYP2C19ALDH1A1TDP1
SCHEMBL15060220 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12529077-B2 Production of geranyl diphosphate-derived compounds Københavns Universitet (DK) 2026-01-20 US claimed
US-12156879-B2 Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy UNIVERSITY OF CONNECTICUT (US) 2024-12-03 US claimed
US-20230159960-A1 Production Of Geranyl Diphosphate-Derived Compounds KOBENHAVNS UNIVERSITET (DK) 2023-05-25 US claimed
CN-115698272-A Production of geranyl diphosphate derived compounds 哥本哈根大学 2023-02-03 CN claimed
US-11059886-B1 Methods and compositions for treating inflammatory or autoimmune diseases or conditions using GRM8 activators FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2021-07-13 US claimed
US-12533425-B2 Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery ALUME BIOSCIENCES, INC. (US) 2026-01-27 US disclosed
US-12529077-B2 Production of geranyl diphosphate-derived compounds Københavns Universitet (DK) 2026-01-20 US disclosed
EP-4632795-A1 CHAMFERING METHOD AND CHAMFERING DEVICE Tokyo Seimitsu Co., Ltd. (JP) 2025-10-15 EP disclosed
WO-2024256282-A1 METHOD FOR DETECTING AN ELECTRIC ARC IN A RESISTIVE HEATING SYSTEM ECM GREENTECH (FR) 2024-12-19 WO disclosed
US-12156879-B2 Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy UNIVERSITY OF CONNECTICUT (US) 2024-12-03 US disclosed
CN-118995530-A Enterococcus casseliflavus and application thereof in promoting tobacco growth and improving tobacco quality 河南农业大学 2024-11-22 CN disclosed
CN-112566906-B Substituted quinazolinone derivatives and their use as positive allosteric modulators of MGLUR4 多曼治疗学公司 2024-11-12 CN disclosed
WO-2010074992-A2 CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS OTONOMY, INC. (US) 2010-07-01 WO disclosed
US-20100137344-A1 INDUCTION OF ANALGESIA IN NEUROPATHIC PAIN UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) 2010-06-03 US disclosed
US-20100022661-A1 CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF OTONOMY, INC. (US) 2010-01-28 US disclosed
US-20100021416-A1 CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS OTONOMY, INC. (US) 2010-01-28 US disclosed
US-20100015263-A1 CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS OTONOMY, INC. (US) 2010-01-21 US disclosed
US-20090306225-A1 AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS OTONOMY, INC. (US) 2009-12-10 US disclosed
US-7129073-B2 Regulation of neuronal function through metabotropic glutamate receptor signaling pathways THE ROCKEFELLER UNIVERSITY (US) 2006-10-31 US disclosed
US-20060223158-A1 REGULATION OF NEURONAL FUNCTION THROUGH METABOTROPIC GLUTAMATE RECEPTOR SIGNALING PATHWAYS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100015263-A1 CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS OTC, MYOC, S100B GRM4 1414/4885CYP1A2 4738/4885CYP2C19 4793/4885
US-12529077-B2 Production of geranyl diphosphate-derived compounds GGPS1, OGA, GBA3 GRM4 2408/4885CYP1A2 239/4885CYP2C19 1325/4885
US-20100022661-A1 CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF OTC, ARG2, COX6A1 GRM4 2836/4885CYP1A2 2820/4885CYP2C19 3504/4885
US-12156879-B2 Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy BACE1, PSEN1, PSEN2 GRM4 17/4885CYP1A2 4795/4885CYP2C19 4723/4885
US-12533425-B2 Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery NGLY1, VGF, GAP43 GRM4 649/4885CYP1A2 4845/4885CYP2C19 4805/4885
US-20090306225-A1 AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS OTC, AQP4, SLC26A4 GRM4 2196/4885CYP1A2 3771/4885CYP2C19 4090/4885
US-20100021416-A1 CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS OTC, TLR3, STING1 GRM4 2217/4885CYP1A2 4316/4885CYP2C19 4387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.